Summit Corporation - Good progress with the OGA inhibitor programme

 

 

Summit Corporation	Update 19th July 2012
Good progress with the OGA inhibitor programme	Speculative Buy     Target price 11p     Key data Price 2.38p 52 week high/low 11.00p/2.25p Primary exchange AIM EPIC SUMM Shares in issue 354.09m Market Cap £8.41m Sector Pharmaceuticals & Biotechnology       Valuation   EV/EBITDA N/A P/E N/A NAV / Share 0.70p TNAV / Share 0.37p     Previous note Initiation of dose-escalation study and achievement of milestone payment     Future event Interim results       Affiliations: None     Important: All disclaimer information can be found on the last page of the document
Summit Corporation is making good progress with its OGA inhibitor programme for the treatment of tauopathies, a group of neurodegerative diseases associated with the pathological aggregation of tau protein in the human brain. The OGA inhibitors were developed using the company's Seglin Technology platform. Given the potential from its drug discovery programmes for the treatment of Duchene Muscular Dystrophy (SMT C1100) and Clostridium difficile (SMT 19969), our stance remains speculative buy. Click to download Full Report
Table: Financial overview Year to 31st January 2011A 2012A 2013E 2014E Revenue (£000) 763 1,765 1,040 6,500 PBT (£000) (5,916) (2,998) (4,744) 2,430 EPS (p) (2.82) (1.51) (1.41 0.88 Dividend (p) 0.00 0.00 0.00 0.00 Yield (%) 0.00 0.00 0.00 0.00 Source: GECR and company.

 

If you do not wish to receive such emails please use the following link to unsubscribe.

UK-Analyst.com is owned by t1ps.com Ltd which is authorised and regulated by the Financial Services Authority

The hot share tips given here are of necessity, general. They cannot relate to the individual circumstances of investors. Anyone considering following the share tips contained here should seek independent advice from a Financial Services Authority authorised Stockbroker or Financial Adviser. So, while we would not wish to reduce our liability under the FSA regulatory regime, we cannot otherwise be held liable if individuals suffer losses through following share tips contained on this site or emailed out as free share tips. The value of investments can go down as well as up. The past is not necessarily a guide to future performance. Investing in shares can lose you part or all of your capital although the potential returns are theoretically unlimited. The difference between the buy share price and the sell share price for smaller company shares (penny shares) can be significant. Profits from dealing in shares may be liable to tax - the level of tax and bases of relief from tax are subject to change. Changes in the rates of exchange may have an adverse effect on the value or price of an investment in sterling terms if it is denominated in a foreign currency. Financial spread betting is a high risk investment, losses from which are potentially unlimited. Some of the shares recommended on this site will be smaller company shares. By their nature such investments can be relatively illiquid and thus hard to trade. And that makes such investments more of a high risk than larger company shares (or 'small caps'/'penny shares'). UK-Analyst.com defines a smaller company share as any stock traded on AIM or PLUS or which has a market capitalisation of less than GBP300 million.